F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Munich, Munich, Germany.
F. Hoffmann-La Roche AG, Pharmaceutical Research and Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.
Clin Cancer Res. 2021 Aug 1;27(15):4147-4159. doi: 10.1158/1078-0432.CCR-20-2345. Epub 2021 Mar 25.
Today, there is a huge effort to develop cancer immunotherapeutics capable of combating cancer cells as well as the biological environment in which they can grow, adapt, and survive. For such treatments to benefit more patients, there is a great need to dissect the complex interplays between tumor cells and the host's immune system. Monitoring mechanisms of resistance to immunotherapeutics can delineate the evolution of key players capable of driving an efficacious antitumor immune response. In doing so, simultaneous and systematic interrogation of multiple biomarkers beyond single biomarker approaches needs to be undertaken. Zooming into cell-to-cell interactions using technological advancements with unprecedented cellular resolution such as single-cell spatial transcriptomics, advanced tissue histology approaches, and new molecular immune profiling tools promises to provide a unique level of molecular granularity of the tumor environment and may support better decision-making during drug development. This review will focus on how such technological tools are applied in clinical settings, to inform the underlying tumor-immune biology of patients and offer a deeper understanding of cancer immune responsiveness to immuno-oncology treatments.
如今，人们正在努力开发能够对抗癌细胞以及它们可以生长、适应和存活的生物环境的癌症免疫疗法。为了使这些治疗方法使更多的患者受益，非常有必要剖析肿瘤细胞与宿主免疫系统之间的复杂相互作用。监测免疫疗法耐药的机制可以描绘出能够驱动有效抗肿瘤免疫反应的关键因素的演变。为此，需要进行超越单一生物标志物方法的同时和系统地检测多个生物标志物。使用单细胞空间转录组学、先进的组织组织学方法和新的分子免疫分析工具等具有前所未有的细胞分辨率的技术进步来放大细胞间的相互作用，有望提供肿瘤环境的独特分子粒度，并在药物开发过程中支持更好的决策。这篇综述将重点介绍这些技术工具如何在临床环境中应用，以告知患者的肿瘤免疫生物学，并深入了解癌症对免疫肿瘤学治疗的免疫反应。
